623143-35-1

Basic information

• Product Name: Benzenemethanamine, alpha-ethyl-3-methoxy-, (alphaS)- (9CI)
• Synonyms: Benzenemethanamine, alpha-ethyl-3-methoxy-, (alphaS)- (9CI);(1S)-1-(3-METHOXYPHENYL)PROPYLAMINE-HCl;(1S)-1-(3-Methoxyphenyl)propylaMine hydrochloride;(S)-1-(3-Methoxyphenyl)propan-1-aMine hydrochloride
• CAS NO: 623143-35-1
• Molecular Formula: C10H15NO
• Molecular Weight: 165.2322
• Product Categories: METHOXY
• Mol File: 623143-35-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 252.9±23.0 °C(Predicted)
• Appearance: /
• Density: 0.988±0.06 g/cm3(Predicted)
• PKA: 9.22±0.10(Predicted)
• CAS DataBase Reference: Benzenemethanamine, alpha-ethyl-3-methoxy-, (alphaS)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanamine, alpha-ethyl-3-methoxy-, (alphaS)- (9CI)(623143-35-1)
• EPA Substance Registry System: Benzenemethanamine, alpha-ethyl-3-methoxy-, (alphaS)- (9CI)(623143-35-1)

Safety Data

• Hazardous Substances Data: 623143-35-1(Hazardous Substances Data)

Usage

General Description

Benzenemethanamine, alpha-ethyl-3-methoxy-, (alphaS)- (9CI) is a chemical compound that is also known as alpha-ethyl-3-methoxyphenethylamine. It is a psychoactive substance that is structurally related to amphetamine and has been identified as an illicit drug in some countries. It is a chiral compound, meaning that it has two distinct enantiomers. The alphaS enantiomer has been found to exhibit stimulant and hallucinogenic effects, and has been associated with a range of adverse health effects including hyperthermia, agitation, and psychosis. It is important to note that the possession, use, and distribution of this chemical may be illegal and can pose serious risks to human health.

Upstream product

• 925-90-6 ethylmagnesium bromide 
• 591-31-1 3-methoxy-benzaldehyde 
• 1527-89-5 3-methoxybenzonitrile 

Relevant articles and documents

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.